IBIO
iBio Inc (IBIO)
Healthcare • NYSE MKT • $1.71+4.27%
- Symbol
- IBIO
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.71
- Daily Change
- +4.27%
- Market Cap
- $61.81M
- Trailing P/E
- N/A
- Forward P/E
- -5.90
- 52W High
- $3.82
- 52W Low
- $0.56
- Analyst Target
- $5.37
- Dividend Yield
- N/A
- Beta
- 1.24
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response ag…
Company websiteResearch IBIO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.